Because SMN2 copy number is a major modifier of SMA disease where the higher SMN2 copy numbers are associated with later onset and milder phenotype, identifying infants with 2 or 3 SMN2 copies and treating at the earliest possible timepoint is critical to ensure the best outcomes. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.